[go: up one dir, main page]

WO2002081638A3 - Prostate cancer expression profiles - Google Patents

Prostate cancer expression profiles Download PDF

Info

Publication number
WO2002081638A3
WO2002081638A3 PCT/US2002/010824 US0210824W WO02081638A3 WO 2002081638 A3 WO2002081638 A3 WO 2002081638A3 US 0210824 W US0210824 W US 0210824W WO 02081638 A3 WO02081638 A3 WO 02081638A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
expression profiles
cancer expression
polynucleotides
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/010824
Other languages
French (fr)
Other versions
WO2002081638A2 (en
Inventor
Zairen Sun
Gilbert Jay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Origene Technologies Inc
Original Assignee
Origene Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origene Technologies Inc filed Critical Origene Technologies Inc
Priority to AU2002307154A priority Critical patent/AU2002307154A1/en
Priority to US10/479,157 priority patent/US20040248116A1/en
Publication of WO2002081638A2 publication Critical patent/WO2002081638A2/en
Publication of WO2002081638A3 publication Critical patent/WO2002081638A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drub discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are differentially-regulated in prostate cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, to prostate cancer.
PCT/US2002/010824 2001-04-06 2002-04-08 Prostate cancer expression profiles Ceased WO2002081638A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002307154A AU2002307154A1 (en) 2001-04-06 2002-04-08 Prostate cancer expression profiles
US10/479,157 US20040248116A1 (en) 2001-04-06 2002-04-08 Prostate cancer expression profiles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28173101P 2001-04-06 2001-04-06
US28173201P 2001-04-06 2001-04-06
US60/281,732 2001-04-06
US60/281,731 2001-04-06

Publications (2)

Publication Number Publication Date
WO2002081638A2 WO2002081638A2 (en) 2002-10-17
WO2002081638A3 true WO2002081638A3 (en) 2003-02-27

Family

ID=26961049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010824 Ceased WO2002081638A2 (en) 2001-04-06 2002-04-08 Prostate cancer expression profiles

Country Status (2)

Country Link
AU (1) AU2002307154A1 (en)
WO (1) WO2002081638A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092009A1 (en) 2000-11-16 2003-05-15 Kaia Palm Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
AU2003225281A1 (en) 2002-04-30 2003-11-17 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
EP1552845A4 (en) * 2002-06-26 2006-06-07 Takeda Pharmaceutical SUBSTANCES FOR THE PREVENTION AND / OR TREATMENT OF CANCER
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
CA2498418A1 (en) * 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
DE10341812A1 (en) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2006113050A2 (en) * 2005-04-12 2006-10-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090269744A1 (en) * 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
JP2010529843A (en) * 2007-06-03 2010-09-02 オンコティーエックス インコーポレイテッド Cancer-associated isoforms of the transcription factor complex as biomarkers and drug targets
US7998688B2 (en) 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
EP3214444A1 (en) * 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORREVOETS ET AL.: "Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin and two novel genes", BLOOD, vol. 93, no. 10, 15 May 1999 (1999-05-15), pages 3418 - 3431, XP002936412 *

Also Published As

Publication number Publication date
WO2002081638A2 (en) 2002-10-17
AU2002307154A1 (en) 2002-10-21

Similar Documents

Publication Publication Date Title
WO2003029421A3 (en) Regulated breast cancer genes
WO2003085095A3 (en) Novel expressed genes
WO2003040331A3 (en) Prostate cancer genes
WO2003063773A3 (en) Differentially-regulated prostate cancer genes
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2002081638A3 (en) Prostate cancer expression profiles
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2004046332A3 (en) Amplified genes involved in cancer
WO2005019264A3 (en) Human lxr alpha variants
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2003016485A3 (en) Full-length serine protein kinase in brain and pancreas
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2003040325A3 (en) Novel proteins and nucleic acids encoding same
EP1186672A3 (en) Polymorphisms in the human organic anion transporter C (OATP-C) gene
WO2003064599A3 (en) Cancer genes
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2003014298A3 (en) Full-length prostate selective polynucleotides and polypeptides
WO2002000691A3 (en) Polynucleotides and polypeptides encoded thereby
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001061055A3 (en) Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
WO2003055980A3 (en) Il-17 like molecules and uses thereof
WO2003066831A3 (en) Angiogenesis genes
WO2003023001A3 (en) Novel proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10479157

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP